The U.S. Food and Drug Administration (FDA) has granted traditional approval to Braftovi (encorafenib) for adult patients ...

Pfizer Inc. PFE shares are trending on Wednesday following the U.S. Food and Drug Administration’s (FDA) full approval of the BRAFTOVI combination regimen for treating metastatic colorectal cancer.

The FDA has approved the first combination, targeted regimen for previously untreated BRAF V600E mutation-positive metastatic colorectal cancer.Encorafenib (Braftovi, Pfizer) plus cetuximab (Erbitux, ...

Adults with differentiated thyroid cancer who are using a GLP-1 for the treatment of diabetes or obesity do not have increased risk for cancer recurrence or progression vs. those not using a GLP-1, ...

Cutting ultrasound referrals for nonpalpable nodules could lead to decreases in incidence ...

Researchers at Memorial Sloan Kettering Cancer Center (MSK) have made an important discovery about how genetic mutations in breast cancer patients can interact and drive resistance to certain drugs ...

In a groundbreaking study published in BME Frontiers , researchers from the University of California, Los Angeles (UCLA), in ...

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

Some anxiety is part of the cost of admission to humanity. Because its distinguishing raison d’etre is the anticipation of bad outcomes, it can be a helpful stimulus to preparation or rehearsal before ...

The FDA approved this combination tablet in the same population late last year based on the AMPLITUDE study data.